Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14645639 | 0.84 | GSK3B (0.56) | CA2GPR35PLA2G4AGSK3BHSD17B3 | |
| SCHEMBL1164781 | 0.84 | GSK3B (0.56) | CA2GPR35PLA2G4AGSK3BHSD17B3 | |
| SCHEMBL14645595 | 0.84 | GSK3B (0.56) | CA2GPR35PLA2G4AGSK3BHSD17B3 | |
| SCHEMBL12374319 | 0.84 | GSK3B (0.56) | CA2GPR35PLA2G4AGSK3BHSD17B3 | |
| SCHEMBL10018136 | 0.83 | GPR35 (0.49) | CA2GPR35PLA2G4AHSD17B3 | |
| SCHEMBL9948832 | 0.83 | GPR35 (0.49) | CA2GPR35PLA2G4AHSD17B3 | |
| SCHEMBL1157000 | 0.81 | GPR35 (0.55) | CA2GPR35PLA2G4ATHRATHRB | |
| SCHEMBL4443826 | 0.77 | GPR35 (0.41) | CA2GPR35PLA2G4A | |
| SCHEMBL1156735 | 0.77 | GPR35 (0.41) | CA2GPR35 | |
| SCHEMBL1363701 | 0.74 | CES2 (0.47) | GPR35PLA2G4AHSD17B3FFAR1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308882-B1 | Fused thiophenes and uses thereof | CORNING INC (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2773646-B1 | CONJUGATED FUSED THIOPHENES, METHODS OF MAKING CONJUGATED FUSED THIOPHENES, AND USES THEREOF | CORNING INC (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-2129678-B1 | FUSED THIOPHENES, METHODS FOR MAKING FUSED THIOPHENES, AND USES THEREOF | CORNING INC (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8846855-B2 | Conjugated fused thiophenes, methods of making conjugated fused thiophenes, and uses thereof | CORNING INCORPORATED (US) | 2014-09-30 | — | — | US | disclosed |
| EP-1799688-B1 | FUSED THIOPHENES, METHODS FOR MAKING FUSED THIOPHENES, AND USES THEREOF | CORNING INC (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130109821-A1 | CONJUGATED FUSED THIOPHENES, METHODS OF MAKING CONJUGATED FUSED THIOPHENES, AND USES THEREOF | CORNING INCORPORATED | 2013-05-02 | — | — | US | disclosed |
| US-20130085256-A1 | FUSED THIOPHENES, METHODS OF MAKING FUSED THIOPHENES, AND USES THEREOF | CORNING INCORPORATED | 2013-04-04 | — | — | US | disclosed |
| US-8389669-B2 | Fused thiophenes, methods for making fused thiophenes, and uses thereof | CORNING INCORPORATED (US) | 2013-03-05 | — | — | US | disclosed |
| US-8349998-B2 | Fused thiophenes, methods for making fused thiophenes, and uses thereof | CORNING INCORPORATED (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| EP-2308882-A1 | Fused thiophenes and uses thereof | Corning Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082278-A1 | FUSED THIOPHENES, METHODS FOR MAKING FUSED THIOPHENES, AND USES THEREOF | HE MINGQIAN | 2011-04-07 | — | — | US | disclosed |
| US-7893191-B2 | Fused thiophenes, methods for making fused thiophenes, and uses thereof | CORNING INCORPORATED (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110040042-A1 | FUSED THIOPHENES, METHODS FOR MAKING FUSED THIOPHENES, AND USES THEREOF | HE MINGQIAN | 2011-02-17 | — | — | US | disclosed |
| US-7838623-B2 | Fused thiophenes, methods for making fused thiophenes, and uses thereof | CORNING INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-7705108-B2 | Fused thiophenes, methods for making fused thiophenes, and uses thereof | CORNING INCORPORATED (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100010237-A1 | FUSED THIOPHENES, METHODS FOR MAKING FUSED THIOPHENES, AND USES THEREOF | HE MINGQIAN | 2010-01-14 | — | — | US | disclosed |
| US-20070265418-A1 | Fused Thiophenes, Methods for Making Fused Thiophenes, and Uses Thereof | CORNING INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| US-20070161776-A1 | Fused thiophenes, methods for making fused thiophenes, and uses thereof | CORNING INCORPORATED | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040042-A1 | FUSED THIOPHENES, METHODS FOR MAKING FUSED THIOPHENES, AND USES THEREOF | TPMT, TST, TYMP | CA2 3208/4885GPR35 4429/4885PLA2G4A 2745/4885 |
| US-20130109821-A1 | CONJUGATED FUSED THIOPHENES, METHODS OF MAKING CONJUGATED FUSED THIOPHENES, AND USES THEREOF | TST, TPMT, TPR | CA2 4373/4885GPR35 4231/4885PLA2G4A 3077/4885 |
| US-20130085256-A1 | FUSED THIOPHENES, METHODS OF MAKING FUSED THIOPHENES, AND USES THEREOF | TPMT, TST, TPR | CA2 4267/4885GPR35 4480/4885PLA2G4A 3304/4885 |
| US-20110082278-A1 | FUSED THIOPHENES, METHODS FOR MAKING FUSED THIOPHENES, AND USES THEREOF | TPMT, TST, TYMP | CA2 3208/4885GPR35 4429/4885PLA2G4A 2745/4885 |
| US-20100010237-A1 | FUSED THIOPHENES, METHODS FOR MAKING FUSED THIOPHENES, AND USES THEREOF | TPMT, TST, TYMP | CA2 3224/4885GPR35 4520/4885PLA2G4A 2866/4885 |
| US-20070265418-A1 | Fused Thiophenes, Methods for Making Fused Thiophenes, and Uses Thereof | TPMT, TST, TYMP | CA2 3208/4885GPR35 4429/4885PLA2G4A 2745/4885 |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | CA2 3178/4885GPR35 1127/4885PLA2G4A 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.